<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cardiac resynchronization therapy and conduction system pacing in heart failure: System implantation and programming
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cardiac resynchronization therapy and conduction system pacing in heart failure: System implantation and programming
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cardiac resynchronization therapy and conduction system pacing in heart failure: System implantation and programming
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bradley P Knight, MD, FACC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan Piccini, MD, MHS, FACC, FAHA, FHRS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 26, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H95141241">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cardiac physiologic pacing (CPP) is defined here as any form of cardiac pacing intended to restore or preserve synchrony of ventricular contraction and includes both conventional cardiac resynchronization therapy (CRT) and the more recently adopted conduction system pacing (CSP). CRT is an established treatment for select patients with chronic heart failure (HF) with both reduced ejection fraction and bundle branch block [
         <a href="#rid1">
          1-4
         </a>
         ]. The traditional definition of CRT involves biventricular or left ventricular (LV)-only pacing. However, His bundle pacing (HBP) and left bundle area pacing (LBAP) can also prevent or mitigate ventricular dyssynchrony that is associated with an underlying bundle branch block or that is created by myocardial ventricular pacing and are broadly referred to as conduction system pacing (CSP) [
         <a href="#rid5">
          5,6
         </a>
         ]. CRT can be achieved with a device designed only for pacing (CRT-P) or with the added capability of defibrillation (CRT-D)  (
         <a class="graphic graphic_diagnosticimage graphicRef116571" href="/z/d/graphic/116571.html" rel="external">
          image 1
         </a>
         ).
        </p>
        <p>
         This topic will review implantation techniques for CRT, LBAP, and HBP systems, as well as the approach to programming.
        </p>
        <p>
         The rationale and indications for CRT in patients with HF are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">
          "Cardiac resynchronization therapy in heart failure: Indications and choice of system", section on 'Rationale for CRT'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">
          "Cardiac resynchronization therapy in heart failure: Indications and choice of system"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3515.html" rel="external">
          "Cardiac resynchronization therapy in atrial fibrillation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2905096015">
         <span class="h1">
          TRADITIONAL CRT WITH A CORONARY SINUS LEAD
         </span>
        </p>
        <p class="headingAnchor" id="H891851574">
         <span class="h2">
          System overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most cardiac resynchronization therapy (CRT) implantations are performed via a transvenous approach with placement of a right atrial (RA) lead, right ventricular (RV) lead, and LV lead  (
         <a class="graphic graphic_diagnosticimage graphicRef116571" href="/z/d/graphic/116571.html" rel="external">
          image 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Right atrial lead
         </strong>
         –
         <strong>
         </strong>
         An atrial lead allows sensing and tracking of the atrial rhythm (either intrinsic or paced atrial rhythm) to appropriately time ventricular activation (ie, allow for atrial contraction before ventricular activation). The RA lead provides atrial pacing as needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with indications for CRT and cardioverter-defibrillator function but who do not require atrial pacing, there are defibrillation leads with floating atrial electrodes with sensing-only function. Devices that use this type of lead are programmed to the VDD pacing mode.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with atrial fibrillation or flutter who have indications for CRT may not require an atrial lead; the absence of functional atrial contraction obviates the need for pacing. The details on CRT in patients with atrial fibrillation are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3515.html" rel="external">
          "Cardiac resynchronization therapy in atrial fibrillation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Right ventricular lead
         </strong>
         –
         <strong>
         </strong>
         The RV lead is an essential component for biventricular pacing systems; its role is to sense the intrinsic ventricular rhythm, pace the RV, and provide tachyarrhythmia therapy in devices capable of such therapy. The optimal programming of the RV lead is described elsewhere in this topic. (See
         <a class="local">
          'Approach to programming'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most RV leads are placed transvenously. The RV lead tip is usually placed in the septum; greater separation from the LV lead improves the ability to synchronize the ventricles [
         <a href="#rid7">
          7
         </a>
         ]; in the case of CRT with defibrillation (CRT-D), this position also provides an optimal shocking vector.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Epicardial placement via a direct surgical approach is another option for RV lead placement; this method of placement is reserved for patients who cannot undergo transvenous placement (eg, due to venous thrombosis) or who require concomitant cardiac surgery (eg, coronary artery bypass grafting). Further details on epicardial lead placement are discussed elsewhere in this topic. (See
         <a class="local">
          'Surgical placement of an epicardial lead'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Left ventricular lead
         </strong>
         –
         <strong>
         </strong>
         In most patients, the cause of dyssynchrony is electrical delay or block in the left-sided His-Purkinje conduction system. Placement of an LV lead via the coronary sinus allows for pacing of the LV, which can restore electrical and mechanical synchrony of ventricular contractions  (
         <a class="graphic graphic_diagnosticimage graphicRef116571" href="/z/d/graphic/116571.html" rel="external">
          image 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulse generator
         </strong>
         –
         <strong>
         </strong>
         The pulse generator connects to the leads to provide pacing stimuli and regulation of the rhythm according to a number of settings and algorithms. The pulse generator contains the battery and the interface for programming changes and is typically placed in the region medial to the deltopectoral groove.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4149373955">
         <span class="h2">
          Procedure for placement
         </span>
         <span class="headingEndMark">
          —
         </span>
         During the placement of a traditional CRT system, the steps include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Appropriate sedation is established. (See
         <a class="medical medical_review" href="/z/d/html/94294.html" rel="external">
          "Anesthetic considerations for electrophysiology procedures", section on 'Procedures for cardiac implantable electronic devices'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Standard central venous access is obtained for each lead to be implanted. Ipsilateral upper extremity contrast venography of the central venous system is often used for guidance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A pocket for the device is surgically created within the plane of the prepectoral fascia below the clavicle. Venous access is obtained from the pocket to the axillary, subclavian, or cephalic vein, and the leads are extended to the RA and RV. Once in place, the leads are anchored to the pectoral muscle.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The LV lead is placed similarly to the RA and RV leads but is placed in the coronary sinus instead of within a cardiac chamber. The placement of the LV lead is typically the most complicated aspect of CRT implantation. The placement of the LV lead consists of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Contrast injections through the guide sheath, fluoroscopic landmarks, or electrophysiologic signals are used to identify the ostium of the coronary sinus. The operator may also identify anatomy such as abnormal position of the coronary sinus ostium, presence of venous valves (eg, Thebesian valve, Valve of Vieussens), or coronary sinus strictures [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The coronary ostium is then accessed with a wire or catheter and the coronary sinus guide sheath is advanced into the coronary sinus. The lead is advanced through the sheath into one of the venous branches for LV pacing based on criteria.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Further details on optimal coronary sinus lead placement are discussed elsewhere in this topic. (See
         <a class="local">
          'Coronary sinus lead positioning'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         The success of de novo CRT system placement is high and associated with the experience of the implanting center. In approximately 5 to 10 percent of implantation attempts, the LV lead cannot be placed.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of de novo transvenous CRT implants among 2014 patients from 114 centers, the overall success rate was 97.1 percent, median fluoroscopic time was 17 minutes, median dye use was 25 mL, and adverse events occurred in 2.6 percent [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an analysis of the National Inpatient Sample Database involving 410,104 de novo CRT implants between 2003 and 2011, lower hospital volume was associated with higher rates of in-hospital mortality [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1618947356">
         <span class="h2">
          Placement issues with preexisting pacing systems
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with a preexisting transvenous pacing or defibrillation system, most patients can undergo addition of a coronary sinus lead by opening the existing pocket, adding a coronary sinus lead, and upgrading the pacing generator as appropriate. However, patients who require addition of a coronary sinus lead (ie, device "upgrade") are more likely to have venous obstruction (prevalence 10 to 30 percent) caused by the existing system that may prevent placement of a coronary sinus lead (10 to 30 percent) [
         <a href="#rid11">
          11-15
         </a>
         ].
        </p>
        <p>
         In patients undergoing device upgrade, regardless of the absence of symptoms suggesting venous stenosis (eg, arm edema), we routinely obtain contrast venography prior to CRT upgrade to aid in procedural planning and execution [
         <a href="#rid14">
          14,16
         </a>
         ].
        </p>
        <p>
         If contrast venography suggests that typical left-sided transvenous coronary sinus lead placement is not feasible, the following strategies may be used to place a coronary sinus lead. The approach to such patients depends on local experience with treatment of the obstruction and the risks of alternative placement strategies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lead extraction and coronary sinus lead placement
         </strong>
         – One common approach is transvenous lead extraction, which can restore venous access, followed by transvenous coronary sinus lead placement and replacement of the extracted lead [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/971.html" rel="external">
          "Cardiac implantable electronic device lead removal"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the LEXICON study of 2405 extracted leads, this approach was associated with clinically successful lead extraction in 97.7 percent, a major adverse event rate of 1.4 percent, and procedural death in 0.28 percent [
         <a href="#rid18">
          18
         </a>
         ]. Risk factors for complications include body mass index &lt;25 kg/m
         <sup>
          2
         </sup>
         and procedures performed at low volume extraction centers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of venous obstruction prior to lead placement
         </strong>
         – Treatment of venous obstruction with percutaneous venoplasty prior to lead implantation may allow for successful CRT upgrade [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Venous cannulation beyond the obstruction
         </strong>
         – This approach requires "deep" transvenous access proximal to the point of obstruction in a more central or medial point. The risks of this approach include vascular or thoracic trauma, pneumothorax, and increased risk of lead fracture on follow-up [
         <a href="#rid19">
          19,20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A related strategy is parasternal or paraclavicular lead tunneling to an alternate point of ipsilateral venous entry. In this strategy, the ipsilateral internal jugular vein serves as the point of entry. Concerns include risk for skin erosion over bony sternal or clavicular prominences where there is typically minimal subcutaneous tissue, which may lead to subsequent transvenous extraction. For these reasons, this approach is rarely utilized.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Surgical placement of an epicardial LV lead
         </strong>
         – Surgical placement of an epicardial LV pacing lead is discussed elsewhere in this topic. (See
         <a class="local">
          'Surgical placement of an epicardial lead'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contralateral implant of a coronary sinus lead or de novo system
         </strong>
         – If upgrade of a left- or right-sided system is not feasible, a new system can be placed on the contralateral side with full or partial abandonment of the preexisting system. To minimize the number of new leads when using the contralateral side, a lone coronary sinus lead can be implanted on the contralateral side and tunneled subcutaneously across the chest to connect to the preexisting device pocket. Disadvantages of abandoned leads include increased risks of venous occlusive disease (eg, superior vena cava stenosis), device-device or lead-lead interactions, and bloodstream infection [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         In aggregate, the ability to safely place a coronary sinus lead in patients with preexisting transvenous cardiac implantable electronic device systems at experienced centers is high:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a contemporary comparative study of 1496 patients at a high-volume tertiary center who were undergoing de novo or upgrade CRT procedures, the rates of procedural success were similar (97 versus 96 percent), as were the rates of complications at 90 days (5.1 versus 4.6 percent) [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an analysis comparing 19,546 CRT upgrades with 464,246 de novo procedures in the United States between 2003 and 2013, the upgrades were independently associated with increased mortality (odds ratio [OR] 1.91), cardiac perforation (OR 3.2), and need for lead revision (OR 2.09) [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the REPLACE registry, the complication rates for procedures involving lead additions, particularly an LV lead, were greater than those for generator replacement alone [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3800164805">
         <span class="h2">
          Coronary sinus lead positioning
         </span>
        </p>
        <p class="headingAnchor" id="H588203690">
         <span class="h3">
          General principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal LV lead location is that at which the lead effectively paces the site of greatest electromechanical delay while avoiding phrenic nerve stimulation. However, the patient’s coronary sinus and LV venous anatomy  (
         <a class="graphic graphic_diagnosticimage graphicRef116573" href="/z/d/graphic/116573.html" rel="external">
          image 2
         </a>
         ) determine where the LV lead can be placed. The most common LV venous anatomy is composed of an anterior vein coursing in the interventricular groove, an anterolateral branch coursing diagonally from the LV base to the apex of the LV, a midlateral and/or posterolateral vein that often shares a common trunk, and the middle cardiac vein coursing posteriorly to the LV apex.
        </p>
        <p>
         The available evidence suggests that the optimal position for the LV lead is generally the lateral or posterolateral wall  (
         <a class="graphic graphic_diagnosticimage graphicRef116573" href="/z/d/graphic/116573.html" rel="external">
          image 2
         </a>
         ). In the presence of left bundle branch block (LBBB), the basal posterolateral wall is often the last segment to contract in a dyssynchronous LV. In the follow-up results of the MADIT CRT study, only patients with lateral and posterior LV lead locations derived long-term mortality benefit from CRT over implantable cardioverter-defibrillator (ICD) alone [
         <a href="#rid24">
          24
         </a>
         ]. Additionally, a more basal pacing site has also been associated with better rates of CRT response.
        </p>
        <p class="headingAnchor" id="H301119642">
         <span class="h3">
          Strategies for optimal lead placement
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, the usual strategy for initial LV placement is guided by anatomy; the lead tip is positioned near the basal position of the lateral wall at a stable site with acceptable pacing parameters and where there is no left phrenic nerve capture. Some implanting clinicians also use electrical or mechanical information including the Q-LV interval  (
         <a class="graphic graphic_figure graphicRef120743" href="/z/d/graphic/120743.html" rel="external">
          figure 1
         </a>
         ) to further direct lead placement and the optimal pacing site.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Site of greatest electrical delay
         </strong>
         – In patients with LBBB, we often target the site of greatest LV electrical delay for pacing stimulation  (
         <a class="graphic graphic_figure graphicRef120743" href="/z/d/graphic/120743.html" rel="external">
          figure 1
         </a>
         ). In patients without LBBB, we do not select the pacing site using the Q-LV interval [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The following studies illustrate the importance of LV electrical delay as measured by Q-LV as a predictor of improvement in hemodynamic improvement:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a prospective acute hemodynamic studies of 31 and 32 patients undergoing CRT implant, Q-LV was strongly associated with hemodynamic improvement as measured by dP/dt max independent of the pacing mode [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a prospective study of 156 patients, Q-LV was the only independent predictor of improvement in LV ejection fraction (LVEF) and decrease in LV end-systolic volume in follow-up [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In an analysis of the SMART AV trial involving 426 patients, Q-LV was associated with greater improvement in mitral regurgitation, suggesting an additional physiologic mechanism for targeting the site of greatest electrical delay [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other methods of pacing site selection
         </strong>
         – Other methods of pacing site selection may play a role but are used less frequently:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Right to left electrical delay
         </strong>
         – The presence of LBBB causes overall delayed LV activation compared with the RV, leading some operators to measure the interlead electrical delay (IED) time, which is the time between sensing of the native impulse at the RV and sensing of the native impulse at the LV lead. In a study of 68 patients, IED was independently associated with CRT response (reverse remodeling), even when accounting for the presence of myocardial scar (OR 3.99, 95% CI 1.02-15.7) [
         <a href="#rid30">
          30
         </a>
         ]. In another study involving 160 patients, an IED ≥100 ms was associated with more pronounced LV reverse remodeling when lead implantation site was guided by identification of the latest mechanical delay in a nonscarred myocardial segment [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Site of greatest mechanical delay
         </strong>
         – After optimizing the site of pacing using the site of greatest electrical delay, some experts evaluate for the site of greatest mechanical delay. Targeting the site of greatest mechanical delay for pacing stimulation has been associated with improved CRT outcomes in some studies:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Echocardiographic-based imaging and magnetic resonance imaging have been utilized to evaluate the value of LV pacing at or near the area of greatest mechanical delay [
         <a href="#rid32">
          32-34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Tissue Doppler imaging has been the most widely studied and utilized method in clinical practice [
         <a href="#rid35">
          35-42
         </a>
         ]. Tissue Doppler imaging was initially assessed in a series of 54 patients, and a greater reduction in end-systolic volume was associated with LV pacing at the site of greatest mechanical delay [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         An additional echocardiographic-based method is myocardial strain imaging [
         <a href="#rid44">
          44,45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5298.html" rel="external">
          "Tissue Doppler echocardiography", section on 'Use in heart failure and resynchronization therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Although direct measures of mechanical dyssynchrony have been investigated as a means of identifying responders to CRT [
         <a href="#rid46">
          46-50
         </a>
         ], the clinical utility of such assessment has not been established.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Avoiding LV scar
         </strong>
         – The optimal position for the LV lead is in the vicinity of viable myocardium that is not in or immediately adjacent to scar tissue. Pacing in regions of LV scar has been associated with lower response rates. In addition, pacing in a densely scarred region may require higher pacing outputs, which can lead to premature battery drain. The burden of scar may influence the efficacy of CRT pacing [
         <a href="#rid32">
          32,51-53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Placement of a quadripolar lead
         </strong>
         – We typically place a quadripolar LV pacing lead. These leads reduce the incidence of phrenic nerve stimulation and improve the likelihood of CRT response by providing an array of options for the site of pacing [
         <a href="#rid54">
          54
         </a>
         ]. Selecting the site for optimal pacing and algorithms that make use of multiple coronary sinus pacing sites are discussed elsewhere in this topic. (See
         <a class="local">
          'Other parameters for optimization'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3938930793">
         <span class="h2">
          Approach to programming
         </span>
        </p>
        <p class="headingAnchor" id="H75567651">
         <span class="h3">
          Initial settings
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, we optimize device settings for the best clinical response and lowest battery use. The optimal device settings at the time of implant are not clearly defined and may be patient specific. The following principles influence our choice of initial programming:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Program the atrioventricular delay to optimize resynchronization
         </strong>
         – For patients who are in sinus rhythm, the pacing mode is typically programmed DDD, DDDR, or VDD depending on the need for atrial pacing. For patients in sinus rhythm and with intact atrioventricular (AV) conduction, the AV delay should be set to a value that minimizes the QRS duration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Increase the frequency of pacing
         </strong>
         – In patients with continuous atrial fibrillation and a relatively high resting ventricular rate, we increase the lower rate limit to target 100 percent CRT pacing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choose the optimal site of pacing
         </strong>
         – We pace the LV at a site with the greatest electrical delay (measured by the Q-LV interval)  (
         <a class="graphic graphic_figure graphicRef120743" href="/z/d/graphic/120743.html" rel="external">
          figure 1
         </a>
         ) that does not result in a wider QRS morphology, LBBB morphology, or apical QRS morphology. The site of pacing should not stimulate the phrenic nerve.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Minimize power consumption
         </strong>
         – We program CRT devices to promote battery longevity by choosing pacing sites with the lowest possible electrical thresholds, lowest impedance measurements, and shortest pulse width. Minimizing RV pacing stimulation with fusion pacing can extend battery longevity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ancillary settings
         </strong>
         – Other pacing settings are available, but routine selection of one method over another is controversial. (See
         <a class="local">
          'Other parameters for optimization'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3695330774">
         <span class="h3">
          Identification of and approach to nonresponders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most experts define nonresponse to CRT as lack of improvement in LVEF or New York Heart Association (NYHA) class. However, other criteria that can be used to identify nonresponders include other measures of LV function (eg, global longitudinal strain), LV dimensions, exercise capacity and functional status, and quality of life [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         For most patients with HF with reduced ejection fraction who do not initially respond to CRT, we evaluate for clinical causes of nonresponse (eg, progressive HF, nonadherence to medical therapy) and adjust therapies as needed. In most patients, the initial approach to nonresponse is to change pacing parameters based on the surface electrocardiogram (ECG). Pacing vectors (ie, sites) are adjusted until the narrowest QRS duration is achieved and there are no signs of an apical pacing morphology (ie, LBBB appearance in V1 with a superior axis that is negative in limbs leads II, III, and aVF with a widened QRS &gt;200 ms).
        </p>
        <p>
         However, optimizing pacing with electrophysiologic parameters does not always translate to a clinical response or improved mechanical synchrony. For example, ventricular scar patterns can create "balanced delay" in which the overall right and left ventricular activations are relatively simultaneous (ie, paced QRS appears narrow) but remain mechanically dyssynchronous due to nonhomogenous conduction through and around intrinsic LV scar.
        </p>
        <p>
         Mismatch between the surrogates for mechanical synchronization (eg, surface ECG parameters) and true mechanical resynchronization likely explain the discrepancy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with little or no intrinsic AV conduction (ie, complete heart block), achieving a more narrowly paced QRS duration was associated with reduction of LV end-systolic volume of ≥15 percent from baseline [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a substudy of the PROSPECT trial, greater shortening of the paced QRS over the intrinsic QRS duration was also associated with significantly increased likelihood of clinical and echocardiographic response (OR 0.89) [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an analysis of the MADIT CRT trial, shortened paced QRS duration was not associated with better outcomes, while apical pacing demonstrated worse outcomes [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H74487105">
         <span class="h3">
          Other parameters for optimization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Options for programming that are used in specific scenarios include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fusion pacing
         </strong>
         – In patients with intact AV conduction and LBBB, fusion pacing can be used rather than standard biventricular pacing. Fusion pacing entails timing LV pacing to coincide with normal RV activation  (
         <a class="graphic graphic_figure graphicRef116574" href="/z/d/graphic/116574.html" rel="external">
          figure 2
         </a>
         ). This is referred to as adaptive CRT. The timing of LV pacing is determined from the sensed time between RA depolarization and RV activation [
         <a href="#rid59">
          59
         </a>
         ]. Thus, fusion-pacing algorithms commonly result in a more narrowly paced QRS than either traditional biventricular pacing or LV-only pacing; the intact right bundle and/or septal His-Purkinje allows more rapid electrical depolarization. A similar algorithm allows for dynamic adjustment of the AV delay to accommodate ventricular remodeling while allowing the option of using varying combinations of LV pacing, RV pacing, and intrinsic conduction (ie, so-called "triple fusion") [
         <a href="#rid60">
          60,61
         </a>
         ]. Fusion pacing is not the same as "LV-only" CRT pacing; the latter ignores RA-RV conduction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with high RV pacing thresholds whose device is capable of fusion pacing, fusion pacing can improve battery longevity and may complement other programming changes directed at preserving battery life.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The evidence on fusion pacing includes two trials that arrived at different conclusions regarding its effect on clinical outcomes, though the larger trial had longer follow-up and showed no clear effect on clinical outcomes:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a trial (AdaptResponse) that enrolled 3617 patients with an LVEF ≤35 percent, NYHA class II to IV symptoms, and LBBB (QRS ≥140 ms in males and ≥130 ms in females), the rates of all cause death or intervention for HF decompensation (ie, primary composite endpoint) were similar in patients assigned to adaptive CRT or to conventional CRT after eight years of observation (23.5 versus 25.5 percent; hazard ratio [HR] 0.89, 95% CI 0.78-1.01) [
         <a href="#rid62">
          62
         </a>
         ]. In a subgroup analysis, patients assigned to adaptive CRT programming were less likely to undergo generator exchange for battery depletion (24 versus 15 percent; HR 0.59, 95% CI 0.47–0.75).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the Adaptive CRT trial, 478 patients were randomized in a 2:1 ratio to fusion pacing (LV pacing synchronized to RV contraction using a proprietary algorithm) versus standard CRT with echocardiographic-guided optimization [
         <a href="#rid60">
          60
         </a>
         ]. At a mean of 20 months of follow-up, the fusion pacing group demonstrated a lower likelihood of all-cause hospitalizations (OR 0.54, 95% CI 0.31-0.94). The effects of programming on battery life were not reported.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Multisite pacing
         </strong>
         – In patients with a quadripolar lead, some experts use the multisite pacing programming (MPP) algorithm. This is typically done at the time of implant. MPP is a proprietary algorithm that simultaneously uses two or more LV pacing configurations to overcome transmyocardial conduction delay or improve intraventricular dyssynchrony.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In an observational study of 110 patients comparing standard with multisite pacing, the one-year echocardiographic response rate with optimally positioned leads was 72 percent with standard programming and 90 percent with MPP [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a meta-analysis of studies comparing MPP with conventional CRT, the use of MPP was associated with decreased HF hospitalizations, improved LVEF, increased CRT response, and decreased all-cause mortality [
         <a href="#rid63">
          63
         </a>
         ]. However, the data from randomized controlled trials are less compelling, and multisite pacing increases the rate of battery depletion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LV-only pacing
         </strong>
         – LV-only pacing is infrequently used in modern practice. Randomized trials that compared LV-only pacing with standard LV pacing (PATH-CHF, DECREASE-HF, B-LEFT HF, GREATER EARTH) showed no advantage of LV-only pacing in patients with LBBB [
         <a href="#rid64">
          64-67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Echocardiographic optimization
         </strong>
         – We do not routinely perform echocardiographic optimization of CRT pacing. There is limited evidence to support routine optimization of CRT pacing with echocardiographic parameters. The approaches to echocardiographic optimization include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          AV optimization
         </strong>
         – For CRT pacing, a shortened AV delay (ie, 90 to 120 ms) reduces the likelihood of native AV conduction and increases the percentage of biventricular pacing. In patients who fail to experience improvement in symptoms or cardiac function following CRT implantation, postprocedural adjustment in the AV delay ("AV optimization") with Doppler echocardiographic assessment may be helpful in highly selected individuals.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The typical strategy is to program the AV delay such that the end of atrial contraction (marked by the end of the A wave) is timed to coincide with the onset of ventricular contraction (marked by the onset of systolic mitral regurgitant flow) [
         <a href="#rid68">
          68
         </a>
         ]. However, the clinical efficacy of AV optimization has not been established, as randomized clinical trials have failed to demonstrate benefit [
         <a href="#rid69">
          69
         </a>
         ]. In a post hoc analysis of the MADIT CRT study involving 1235 patients, sensed AV delays less than 120 ms demonstrated overall better clinical outcomes when compared with longer sensed AV delays, likely attributable to a greater percentage of biventricular pacing in place of intrinsic activation via the native diseased His-Purkinje system [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          VV optimization
         </strong>
         – With CRT devices, the timing between the right and left ventricular pacing stimulus (VV timing) can be adjusted, but the optimal programming strategies for VV timing have not been fully defined and may be patient specific. There is limited evidence to support routine adjustment of VV timing using echocardiographic parameters.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H241385753">
         <span class="h2">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The complications of CRT pacing include coronary sinus or coronary vein trauma, pneumothorax, pocket hematoma, infection, and phrenic nerve pacing [
         <a href="#rid71">
          71-74
         </a>
         ]. There are also specific concerns with LV lead placement, such as prolonged radiation exposure due to long procedure times in challenging cases [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postoperative
         </strong>
         – CRT implantation complication rates varied among studies but appear to be higher with CRT upgrades [
         <a href="#rid22">
          22
         </a>
         ] and lower among high-volume centers [
         <a href="#rid10">
          10
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a study of 2014 patients from 114 centers undergoing de novo transvenous CRT implant, the composite complication rate was 2.6 percent at three months, most commonly involving LV lead dislodgement in 1.7 percent of patients and phrenic nerve stimulation not amenable to reprogramming in 0.5 percent of patients [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A meta-analysis of clinical trials, albeit among older studies, reported an overall acute complication rate of 14 percent that is largely driven by lead-related complications but also includes 0.8 percent perioperative mortality [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         With regard to CRT upgrades, one study found an acute complication rate of 11 percent [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The REPLACE Registry was a larger multicenter study of 1700 patients [
         <a href="#rid23">
          23
         </a>
         ]. The major complication rate was 4 percent for isolated generator change, 15 percent for addition or revision of a lead along with generator change, and 19 percent if the lead revised was the LV lead.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Higher in-hospital mortality rates were observed in a cohort of 26,887 patients undergoing ICD and/or CRT implantation that included older adults with rates ranging from 0.7 to 1.2 to 2.2 percent in patients aged &lt;80, 80 to 85, and &gt;85 years [
         <a href="#rid78">
          78
         </a>
         ]. While patients over 80 years old undergoing CRT implantation may face higher complication rates than younger patients, longer-term data suggest that mortality rates for these patients are only slightly higher than in the general octogenarian population.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Long-term
         </strong>
         – The long-term complications of CRT include device malfunction and infection. The incidence of late complications is illustrated by the following results from a review of implantation success rates and safety outcomes in studies of patients undergoing CRT or CRT-D implantation [
         <a href="#rid73">
          73
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In 54 studies (6123 patients) of CRT-alone devices, 5 percent of CRT devices malfunctioned, and 2 percent of patients were hospitalized for infections in the implant site over six months of follow-up. During a median follow-up of 11 months, lead problems occurred in 7 percent of CRT devices.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         While there is a theoretical risk that pacing from an LV lead may be proarrhythmic due to alterations in depolarization and repolarization sequences (eg, "dispersion of refractoriness"), a pooled analysis from 14 randomized controlled trials did not demonstrate any excess risk of sudden death or noncardiac death in CRT device recipients, on average [
         <a href="#rid79">
          79
         </a>
         ]. However, there are cases of individual patients who experience ventricular tachycardia storm after CRT is activated.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In 36 studies (5199 patients) of combined CRT-D devices, 5 percent of CRT-D devices malfunctioned, 1 percent of patients developed site infection, and lead problems were detected in 7 percent of patients over 12 months of follow-up.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H284782145">
         <span class="h1">
          SURGICAL PLACEMENT OF AN EPICARDIAL LEAD
         </span>
        </p>
        <p class="headingAnchor" id="H3025046226">
         <span class="h2">
          System overview
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epicardial cardiac resynchronization therapy (CRT) systems involve placement of a pacing lead directly on the lateral LV epicardium via a thoracotomy or thorascopically. The RA and RV leads are usually transvenous, but in some patients are also placed epicardially. These leads are connected to a pulse generator that provides pulse stimuli and programming.
        </p>
        <p>
         Epicardial lead placement is reserved for patients in whom a coronary sinus lead cannot be placed (eg, venous occlusive disease, anatomy incompatible with coronary sinus lead placement). In rare cases, patients with an indication for CRT may undergo surgical lead placement at the time of concomitant cardiac surgery (eg, valve surgery, coronary artery bypass grafting).
        </p>
        <p>
         Additional details on the indications for epicardial lead placement are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">
          "Cardiac resynchronization therapy in heart failure: Indications and choice of system", section on 'Alternative approaches'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2602823501">
         <span class="h2">
          Procedure and lead placement
         </span>
         <span class="headingEndMark">
          —
         </span>
         The technique for surgical LV lead placement includes a mini-thoracotomy approach in the fourth or fifth intercostal space anterior to the midaxillary line. Typically, single lung ventilation is performed to allow dissection into the pericardial space for implantation of the epicardial LV lead [
         <a href="#rid80">
          80
         </a>
         ]. It is important that the lead be placed at a basal lateral location. The lead is fixed directly to the cardiac tissue using a specifically designed instrument and tested in the same manner as leads placed via a transvenous approach. A key advantage of surgical epicardial lead placement is that lead placement is not confined to the anatomic branches of the LV venous circulation as is the case with transvenous placement. (See
         <a class="local">
          'General principles'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H100305589">
         <span class="h2">
          Programming
         </span>
         <span class="headingEndMark">
          —
         </span>
         In nearly all cases, the programming of epicardial CRT systems is the same as coronary sinus systems. (See
         <a class="local">
          'Approach to programming'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H955528100">
         <span class="h2">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epicardial lead placement entails an increased risk of adverse events and provides no greater benefit compared with transvenous placement. The risk of surgical lead placement is variable; some centers report complication rates similar to transvenous lead placement, while others report a much higher mortality rate than expected with transvenous lead placement:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 30 patients who underwent cardiac surgery for isolated LV lead placement via a mini-thoracotomy following failed transvenous placement, the epicardial lead placement was successful in all patients and perioperative mortality was zero. However, this study did not report electrical lead testing data, rate of bleeding, or infectious complication rate [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 42 patients with "stand-alone" LV epicardial lead placement using a mini-thoracotomy approach, the mean length of stay was 3.4 days, and the 30-day adverse event rate was 17.5 percent; the adverse events included 4.8 percent mortality, 7.5 percent LV lead noncapture, and 5 percent infection [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A five-year study compared 895 patients who received a transvenous coronary sinus lead with 158 patients who received an epicardial LV lead and found a lead revision was performed in only 2 percent of patients with an epicardial lead compared with 10 percent of patients with a transvenous lead [
         <a href="#rid83">
          83
         </a>
         ]. However, the threshold to revise an epicardial lead is likely higher compared to a transvenous lead.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A study that compared patients with surgically placed epicardial LV leads with transvenously placed leads found no difference over a mean five years of follow-up in which the overall clinical response rate to CRT pacing was 65 percent [
         <a href="#rid84">
          84
         </a>
         ]. In this study, major adverse events occurred in 5 percent of patients undergoing stand-alone LV lead placement and 14 percent of patients with concomitant LV lead placement.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3603898209">
         <span class="h1">
          HIS BUNDLE PACING
         </span>
        </p>
        <p class="headingAnchor" id="H1077563390">
         <span class="h2">
          Components of His bundle pacing systems
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of His bundle pacing is to capture the His-Purkinje system to improve ventricular synchrony. His bundle pacing (HBP) either "directly" (ie, selectively) stimulates the His-Purkinje system or results in para-Hisian (ie, nonselective) stimulation that captures both the His-Purkinje system and adjacent RV myocardium [
         <a href="#rid85">
          85
         </a>
         ]. The use of His bundle pacing in patients in who cannot undergo coronary sinus lead placement is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">
          "Cardiac resynchronization therapy in heart failure: Indications and choice of system", section on 'Alternative approaches'
         </a>
         .)
        </p>
        <p>
         In a HBP system, the RV lead is placed directly into the proximal septum at the location of the bundle of His. If indicated, an RA lead is placed in a manner similar to coronary sinus systems. (See
         <a class="local">
          'System overview'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1039475352">
         <span class="h2">
          Lead placement
         </span>
         <span class="headingEndMark">
          —
         </span>
         His bundle leads are placed in the septum and are guided by pacing maneuvers to confirm His capture. After establishing sedation and transvenous access similar to coronary sinus leads, placement of a His bundle lead consists of the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A pacing lead is advanced through a delivery system to a site on the atrial side of the tricuspid valve annulus or beyond the annulus in the anteroseptal RV.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Next, the His bundle pacing site is evaluated using electrograms recorded from the candidate lead and the ECG that results from pacing [
         <a href="#rid5">
          5,86
         </a>
         ]. Published criteria suggest that the His Bundle pacing should result in a QRS duration less than ≤120 ms and ideally include a 20 to 40 ms isoelectric segment between the pacing stimulus and the QRS complex. Variants of this HBP technique include the use of a diagnostic electrophysiology catheter as a fluoroscopic reference, injection of intravenous contrast, or the use of an electroanatomic mapping system [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Placement of a His pacing system is successful in approximately 50 to 80 percent of attempts, though experience with this approach continues to develop:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a meta-analysis of retrospective studies, HBP for conduction system pacing (CSP) had an average implant success rate of 80 percent and was associated with mean paced QRS duration 122.9±12.0 ms [
         <a href="#rid5">
          5
         </a>
         ]. Compared with baseline values, there were improvements in LVEF, LV volumes, and HF symptoms. The most common complication was an increase in capture thresholds during follow-up.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the His-SYNC pilot trial that included 41 patients with HF and left bundle branch block (LBBB), patients assigned to HBP and biventricular cardiac resynchronization therapy (CRT; ie, CRT with a coronary sinus lead) had similar New York Heart Association class and Kansas City Cardiomyopathy Questionnaire scores during follow-up [
         <a href="#rid87">
          87
         </a>
         ]. However, many patients (48 percent) randomized to HBP crossed over to biventricular CRT due to inability to correct the native LBBB with HBP, and many patients (26 percent) randomized to biventricular CRT crossed over to HBP due to anatomic difficulties, which limits the external validity of the results.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H950141047">
         <span class="h2">
          Programming
         </span>
         <span class="headingEndMark">
          —
         </span>
         Programming is guided by the underlying indication for the pacemaker. During evaluation and programming, it is important to distinguish between septal capture, nonselective His capture, and His bundle capture during threshold testing. However, studies have shown that programming the pacemaker outputs to achieve selective His bundle capture does not provide better outcomes compared with nonselective capture [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2746282667">
         <span class="h2">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uncommon but unique complications of HBP include atrial oversensing and high pacing thresholds [
         <a href="#rid89">
          89,90
         </a>
         ]. There are limited data that compare complications among patients undergoing cardiac physiologic pacing (CPP).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Atrial oversensing
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High pacing thresholds
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4156006978">
         <span class="h1">
          LEFT BUNDLE AREA PACING
         </span>
        </p>
        <p class="headingAnchor" id="H947894372">
         <span class="h2">
          Components of left bundle area pacing systems
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of left bundle area pacing (LBAP) is to provide conduction system pacing (CSP) by stimulating the native cardiac conduction system to partially overcome intrinsic bundle branch block or interventricular conduction delay. The indications for LBAP pacing systems are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">
          "Cardiac resynchronization therapy in heart failure: Indications and choice of system", section on 'Choice of CRT system'
         </a>
         .)
        </p>
        <p>
         LBAP systems are composed of an RV lead that paces in the area of the left bundle and, if indicated, a standard RA lead.
        </p>
        <p class="headingAnchor" id="H4282974846">
         <span class="h2">
          Lead placement
         </span>
         <span class="headingEndMark">
          —
         </span>
         LBAP leads are placed deeply in the proximal RV septum and are tested to confirm left bundle branch capture. Left bundle lead placement also requires 12-lead procedural ECG recording and a delivery sheath or catheter and should only be implanted by experienced operators and in accordance with published techniques, criteria, and applicable equipment [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The delivery system is first advanced into the RV over a guidewire. A transvenous pacing lead with either an extendable-retractable or fixed screw is then advanced through the delivery system to the appropriate location on the RV septum.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The candidate location is selected beginning approximately 1 to 1.5 cm distal (apical) and inferior of the location of the His bundle.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unipolar pacing from the initial candidate endocardial location allows recording of the baseline impedance, 12-lead ECG of the paced QRS morphology, and LV activation time (LVAT) as measured from the pacing stimulus to the peak depolarization in leads V5 to V6. Initial pacing prior to screw fixation is expected to yield an overall left bundle branch block (LBBB)-pattern QRS complex with characteristic "w" pattern in lead V1.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The lead is then advanced into the septum with periodic pacing to evaluate for an ECG morphology consistent with left bundle capture. Contrast venography, unipolar ring pacing, and impedance measurements can help identify the depth in the septum and whether the lead has penetrated into the LV cavity  (
         <a class="graphic graphic_diagnosticimage graphicRef141249" href="/z/d/graphic/141249.html" rel="external">
          image 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The final location is accepted in accordance with published standards, but generally includes evidence of left bundle capture as assessed by a relatively narrow QRS duration and RBBB or rsr’ morphology in V1, and LVAT ≤80 ms in V5 or V6.
        </p>
        <p>
        </p>
        <p>
         In a prospective study of 63 patients with HF and complete LBBB, CSP was successfully achieved in 97 percent with LBAP, resulting in QRS narrowing to mean 118±12 ms associated with improvements in LVEF, volumes, and HF symptoms. Normalization of LVEF ≥50 percent occurred in 75 percent of patients [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1563211498">
         <span class="h2">
          Programming
         </span>
         <span class="headingEndMark">
          —
         </span>
         Programming is guided by the underlying indication for the pacemaker. During evaluation and programming, it is important to distinguish between septal capture and left bundle capture [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H457773968">
         <span class="h2">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The complications of LBAP leads are similar to those of His bundle pacing (HBP) leads (see
         <a class="local">
          'Complications'
         </a>
         above), but LBAP usually has better pacing thresholds and lower risk of atrial oversensing.
        </p>
        <p>
         Because LBAP pacing leads are placed more distally and deeper in the septum, the risks of septal perforation are higher than those observed with HBP leads [
         <a href="#rid93">
          93
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H961617948">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">
          "Society guideline links: Arrhythmias in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/112356.html" rel="external">
          "Society guideline links: Cardiac implantable electronic devices"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6757819">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/16656.html" rel="external">
          "Patient education: Cardiac resynchronization therapy (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Types of cardiac physiologic pacing:
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Definitions
         </strong>
         – Cardiac physiologic pacing (CPP) is defined as any form of cardiac pacing intended to restore or preserve synchrony of ventricular contraction. CPP can be achieved with cardiac resynchronization therapy (CRT) or by engaging the intrinsic conduction system via conduction system pacing (CSP), which includes His bundle pacing (HBP) or left bundle branch area pacing (LBAP). CRT is most commonly achieved by biventricular pacing using a coronary sinus branch or epicardial left ventricular (LV) pacing lead.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Traditional resynchronization systems with a coronary sinus lead
         </strong>
         – Most cardiac resynchronization therapy (CRT) implantations are performed via a transvenous approach in which leads are placed in the right atrium (RA), right ventricle (RV), and coronary sinus (ie, left ventricular [LV] pacing lead)  (
         <a class="graphic graphic_diagnosticimage graphicRef116571" href="/z/d/graphic/116571.html" rel="external">
          image 1
         </a>
         ). (See
         <a class="local">
          'Traditional crt with a coronary sinus lead'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The coronary sinus lead is typically placed at the site of greatest electromechanical delay while avoiding phrenic nerve stimulation. (See
         <a class="local">
          'General principles'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Surgical placement of an epicardial lead
         </strong>
         – Epicardial CRT systems are composed of transvenous leads in the RA and RV and a lead placed directly on the lateral LV epicardium via a thoracotomy. (See
         <a class="local">
          'Surgical placement of an epicardial lead'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The indications for epicardial lead placement are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">
          "Cardiac resynchronization therapy in heart failure: Indications and choice of system", section on 'Alternative approaches'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          His bundle pacing
         </strong>
         – The goal of HBP is to enable pacing and capture of the His-Purkinje system, which can improve synchrony and ventricular activation. His bundle leads are placed in the septum and are guided by pacing maneuvers to confirm His capture. (See
         <a class="local">
          'Components of His bundle pacing systems'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The use of HBP in patients in whom a coronary sinus lead cannot be placed is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">
          "Cardiac resynchronization therapy in heart failure: Indications and choice of system", section on 'Alternative approaches'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Left bundle area pacing
         </strong>
         – The goal of left bundle area pacing (LBAP) is to provide CSP by stimulating the native cardiac conduction system to partially overcome intrinsic bundle branch block or interventricular conduction delay. LBAP systems are composed of an RV lead that paces in the area of the left bundle and, if indicated, a standard RA lead. (See
         <a class="local">
          'Components of left bundle area pacing systems'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The indications for LBAP pacing systems are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">
          "Cardiac resynchronization therapy in heart failure: Indications and choice of system", section on 'Choice of CRT system'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial program settings
         </strong>
         – In general, we optimize device settings for the best clinical response and lowest battery use. The optimal program settings at the time of implant have not been fully defined and may be patient specific. Initial programming includes (see
         <a class="local">
          'Initial settings'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Program the atrioventricular delay to optimize resynchronization
         </strong>
         – For patients who are in sinus rhythm, the pacing mode is typically programmed DDD, DDDR, or VDD depending on the need for atrial pacing. For patients in sinus rhythm and with intact atrioventricular (AV) conduction, the AV delay should be set to a value that minimizes the QRS duration.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         During implantation and follow-up of patients with CPP devices, it is essential to electrocardiographically demonstrate biventricular (for CRT) or conduction system (for CSP) capture.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Increase the frequency of pacing
         </strong>
         – In patients with relatively high resting heart rate or continuous atrial fibrillation, we increase the lower rate limit to target 100 percent CRT pacing.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Choose the optimal site of coronary sinus lead pacing
         </strong>
         – We pace the LV at a site with the greatest electrical delay (measured by the Q-LV interval)  (
         <a class="graphic graphic_figure graphicRef120743" href="/z/d/graphic/120743.html" rel="external">
          figure 1
         </a>
         ) that does not result in a wider QRS morphology, left bundle branch block (LBBB) morphology, or apical QRS morphology. The site of pacing should not stimulate the phrenic nerve.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Minimize power consumption
         </strong>
         – We program CPP devices to promote battery longevity by choosing pacing sites with the lowest possible electrical thresholds, lowest impedance measurements, and shortest pulse width.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Ancillary settings
         </strong>
         – Other pacing settings are available, but routine selection of one method over another is controversial. (See
         <a class="local">
          'Other parameters for optimization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CRT nonresponse
         </strong>
         – Most experts define nonresponse to CRT as lack of improvement in LV ejection fraction (LVEF) or New York Heart Association (NYHA) class. (See
         <a class="local">
          'Identification of and approach to nonresponders'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial approach to nonresponders
         </strong>
         – For most patients with HF with reduced ejection fraction who do not initially respond to CRT, we evaluate for causes of nonresponse and adjust settings as appropriate. In most patients, the initial approach to nonresponse is to change pacing parameters based on the surface ECG. (See
         <a class="local">
          'Identification of and approach to nonresponders'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Additional programming
         </strong>
         – If a response to CRT is not achieved with optimization of the surface ECG, other parameters may be adjusted on an individual basis (eg, fusion pacing, multisite pacing, echocardiographic optimization). (See
         <a class="local">
          'Other parameters for optimization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3835156786">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Leslie A Saxon, MD, Teresa DeMarco, MD, Wilson Colucci, MD, and Daniel J Cantillon, MD, FACC, HRS, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Leclercq C, Kass DA. Retiming the failing heart: principles and current clinical status of cardiac resynchronization. J Am Coll Cardiol 2002; 39:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abraham WT, Hayes DL. Cardiac resynchronization therapy for heart failure. Circulation 2003; 108:2596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jarcho JA. Resynchronizing ventricular contraction in heart failure. N Engl J Med 2005; 352:1594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung MK, Patton KK, Lau CP, et al. 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. Heart Rhythm 2023; 20:e17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qi J, Jia X, Wang Z. His bundle pacing for cardiac resynchronization therapy: a systematic literature review and meta-analysis. J Interv Card Electrophysiol 2020; 59:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang W, Wu S, Vijayaraman P, et al. Cardiac Resynchronization Therapy in Patients With Nonischemic Cardiomyopathy Using Left Bundle Branch Pacing. JACC Clin Electrophysiol 2020; 6:849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ariga R, Tayebjee MH, Benfield A, et al. Greater three-dimensional ventricular lead tip separation is associated with improved outcome after cardiac resynchronization therapy. Pacing Clin Electrophysiol 2010; 33:1490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strohmer B. Valve of Vieussens: an obstacle for left ventricular lead placement. Can J Cardiol 2008; 24:e63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hummel JD, Coppess MA, Osborn JS, et al. Real-World Assessment of Acute Left Ventricular Lead Implant Success and Complication Rates: Results from the Attain Success Clinical Trial. Pacing Clin Electrophysiol 2016; 39:1246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeo I, Kim LK, Lerman BB, Cheung JW. Impact of institutional procedural volume on inhospital outcomes after cardiac resynchronization therapy device implantation: US national database 2003-2011. Heart Rhythm 2017; 14:1826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santini M, Di Fusco SA, Santini A, et al. Prevalence and predictor factors of severe venous obstruction after cardiovascular electronic device implantation. Europace 2016; 18:1220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Worley SJ. Implant venoplasty: dilation of subclavian and coronary veins to facilitate device implantation: indications, frequency, methods, and complications. J Cardiovasc Electrophysiol 2008; 19:1004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abu-El-Haija B, Bhave PD, Campbell DN, et al. Venous Stenosis After Transvenous Lead Placement: A Study of Outcomes and Risk Factors in 212 Consecutive Patients. J Am Heart Assoc 2015; 4:e001878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Rooden CJ, Molhoek SG, Rosendaal FR, et al. Incidence and risk factors of early venous thrombosis associated with permanent pacemaker leads. J Cardiovasc Electrophysiol 2004; 15:1258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lickfett L, Bitzen A, Arepally A, et al. Incidence of venous obstruction following insertion of an implantable cardioverter defibrillator. A study of systematic contrast venography on patients presenting for their first elective ICD generator replacement. Europace 2004; 6:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nemer DM, Patel DR, Madden RA, et al. Comparative Analysis of Procedural Outcomes and Complications Between De Novo and Upgraded Cardiac Resynchronization Therapy. JACC Clin Electrophysiol 2021; 7:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gula LJ, Ames A, Woodburn A, et al. Central venous occlusion is not an obstacle to device upgrade with the assistance of laser extraction. Pacing Clin Electrophysiol 2005; 28:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wazni O, Epstein LM, Carrillo RG, et al. Lead extraction in the contemporary setting: the LExICon study: an observational retrospective study of consecutive laser lead extractions. J Am Coll Cardiol 2010; 55:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antonelli D, Freedberg NA, Turgeman Y. Supraclavicular vein approach to overcoming ipsilateral chronic subclavian vein obstruction during pacemaker-ICD lead revision or upgrading. Europace 2010; 12:1596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aleksic I, Kottenberg-Assenmacher E, Kienbaum P, et al. The innominate vein as alternative venous access for complicated implantable cardioverter defibrillator revisions. Pacing Clin Electrophysiol 2007; 30:957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borek PP, Wilkoff BL. Pacemaker and ICD leads: strategies for long-term management. J Interv Card Electrophysiol 2008; 23:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheung JW, Ip JE, Markowitz SM, et al. Trends and outcomes of cardiac resynchronization therapy upgrade procedures: A comparative analysis using a United States National Database 2003-2013. Heart Rhythm 2017; 14:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poole JE, Gleva MJ, Mela T, et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation 2010; 122:1553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kutyifa V, Kosztin A, Klein HU, et al. Left Ventricular Lead Location and Long-Term Outcomes in Cardiac Resynchronization Therapy Patients. JACC Clin Electrophysiol 2018; 4:1410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh JP, Berger RD, Doshi RN, et al. Targeted Left Ventricular Lead Implantation Strategy for Non-Left Bundle Branch Block Patients: The ENHANCE CRT Study. JACC Clin Electrophysiol 2020; 6:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gold MR, Leman RB, Wold N, et al. The effect of left ventricular electrical delay on the acute hemodynamic response with cardiac resynchronization therapy. J Cardiovasc Electrophysiol 2014; 25:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zanon F, Baracca E, Pastore G, et al. Determination of the longest intrapatient left ventricular electrical delay may predict acute hemodynamic improvement in patients after cardiac resynchronization therapy. Circ Arrhythm Electrophysiol 2014; 7:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaypakli O, Koç M, Gözübüyük G, Şahin DY. High Left Ventricular Lead Sensing Delay Predicts QRS Narrowing and Good Response to Cardiac Resynchronization Therapy. Pacing Clin Electrophysiol 2016; 39:1317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chatterjee NA, Gold MR, Waggoner AD, et al. Longer Left Ventricular Electric Delay Reduces Mitral Regurgitation After Cardiac Resynchronization Therapy: Mechanistic Insights From the SMART-AV Study (SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy). Circ Arrhythm Electrophysiol 2016; 9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tahri JB, Hansen TF, Storkås HS, et al. Interlead electrical delays and scar tissue: Response to cardiac resynchronization therapy in patients with ischemic cardiomyopathy. Pacing Clin Electrophysiol 2019; 42:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sommer A, Kronborg MB, Nørgaard BL, et al. Longer inter-lead electrical delay is associated with response to cardiac resynchronization therapy in patients with presumed optimal left ventricular lead position. Europace 2018; 20:1630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bleeker GB, Kaandorp TA, Lamb HJ, et al. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation 2006; 113:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lardo AC, Abraham TP, Kass DA. Magnetic resonance imaging assessment of ventricular dyssynchrony: current and emerging concepts. J Am Coll Cardiol 2005; 46:2223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalil S, Stegemann B, Muhyaldeen S, et al. Intraventricular dyssynchrony predicts mortality and morbidity after cardiac resynchronization therapy: a study using cardiovascular magnetic resonance tissue synchronization imaging. J Am Coll Cardiol 2007; 50:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bax JJ, Bleeker GB, Marwick TH, et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 2004; 44:1834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kapetanakis S, Kearney MT, Siva A, et al. Real-time three-dimensional echocardiography: a novel technique to quantify global left ventricular mechanical dyssynchrony. Circulation 2005; 112:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cho GY, Song JK, Park WJ, et al. Mechanical dyssynchrony assessed by tissue Doppler imaging is a powerful predictor of mortality in congestive heart failure with normal QRS duration. J Am Coll Cardiol 2005; 46:2237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Penicka M, Bartunek J, De Bruyne B, et al. Improvement of left ventricular function after cardiac resynchronization therapy is predicted by tissue Doppler imaging echocardiography. Circulation 2004; 109:978.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bordachar P, Lafitte S, Reuter S, et al. Echocardiographic parameters of ventricular dyssynchrony validation in patients with heart failure using sequential biventricular pacing. J Am Coll Cardiol 2004; 44:2157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu CM, Fung JW, Zhang Q, et al. Tissue Doppler imaging is superior to strain rate imaging and postsystolic shortening on the prediction of reverse remodeling in both ischemic and nonischemic heart failure after cardiac resynchronization therapy. Circulation 2004; 110:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Notabartolo D, Merlino JD, Smith AL, et al. Usefulness of the peak velocity difference by tissue Doppler imaging technique as an effective predictor of response to cardiac resynchronization therapy. Am J Cardiol 2004; 94:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mele D, Pasanisi G, Capasso F, et al. Left intraventricular myocardial deformation dyssynchrony identifies responders to cardiac resynchronization therapy in patients with heart failure. Eur Heart J 2006; 27:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy RT, Sigurdsson G, Mulamalla S, et al. Tissue synchronization imaging and optimal left ventricular pacing site in cardiac resynchronization therapy. Am J Cardiol 2006; 97:1615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suffoletto MS, Dohi K, Cannesson M, et al. Novel speckle-tracking radial strain from routine black-and-white echocardiographic images to quantify dyssynchrony and predict response to cardiac resynchronization therapy. Circulation 2006; 113:960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyazaki C, Powell BD, Bruce CJ, et al. Comparison of echocardiographic dyssynchrony assessment by tissue velocity and strain imaging in subjects with or without systolic dysfunction and with or without left bundle-branch block. Circulation 2008; 117:2617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Achilli A, Sassara M, Ficili S, et al. Long-term effectiveness of cardiac resynchronization therapy in patients with refractory heart failure and "narrow" QRS. J Am Coll Cardiol 2003; 42:2117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bleeker GB, Holman ER, Steendijk P, et al. Cardiac resynchronization therapy in patients with a narrow QRS complex. J Am Coll Cardiol 2006; 48:2243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu CM, Chan YS, Zhang Q, et al. Benefits of cardiac resynchronization therapy for heart failure patients with narrow QRS complexes and coexisting systolic asynchrony by echocardiography. J Am Coll Cardiol 2006; 48:2251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kass DA. Predicting cardiac resynchronization response by QRS duration: the long and short of it. J Am Coll Cardiol 2003; 42:2125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bax JJ, Abraham T, Barold SS, et al. Cardiac resynchronization therapy: Part 1--issues before device implantation. J Am Coll Cardiol 2005; 46:2153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adelstein EC, Saba S. Scar burden by myocardial perfusion imaging predicts echocardiographic response to cardiac resynchronization therapy in ischemic cardiomyopathy. Am Heart J 2007; 153:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salden OAE, van den Broek HT, van Everdingen WM, et al. Multimodality imaging for real-time image-guided left ventricular lead placement during cardiac resynchronization therapy implantations. Int J Cardiovasc Imaging 2019; 35:1327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sweeney MO, van Bommel RJ, Schalij MJ, et al. Analysis of ventricular activation using surface electrocardiography to predict left ventricular reverse volumetric remodeling during cardiac resynchronization therapy. Circulation 2010; 121:626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oswald H, Asbach S, Köbe J, et al. Effectiveness and Reliability of Selected Site Pacing for Avoidance of Phrenic Nerve Stimulation in CRT Patients with Quadripolar LV Leads: The EffaceQ Study. Pacing Clin Electrophysiol 2015; 38:942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fornwalt BK, Sprague WW, BeDell P, et al. Agreement is poor among current criteria used to define response to cardiac resynchronization therapy. Circulation 2010; 121:1985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rickard J, Cheng A, Spragg D, et al. QRS narrowing is associated with reverse remodeling in patients with chronic right ventricular pacing upgraded to cardiac resynchronization therapy. Heart Rhythm 2013; 10:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsing JM, Selzman KA, Leclercq C, et al. Paced left ventricular QRS width and ECG parameters predict outcomes after cardiac resynchronization therapy: PROSPECT-ECG substudy. Circ Arrhythm Electrophysiol 2011; 4:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh JP, Klein HU, Huang DT, et al. Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. Circulation 2011; 123:1159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birnie D, Lemke B, Aonuma K, et al. Clinical outcomes with synchronized left ventricular pacing: analysis of the adaptive CRT trial. Heart Rhythm 2013; 10:1368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Starling RC, Krum H, Bril S, et al. Impact of a Novel Adaptive Optimization Algorithm on 30-Day Readmissions: Evidence From the Adaptive CRT Trial. JACC Heart Fail 2015; 3:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zanon F, Marcantoni L, Baracca E, et al. Optimization of left ventricular pacing site plus multipoint pacing improves remodeling and clinical response to cardiac resynchronization therapy at 1 year. Heart Rhythm 2016; 13:1644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilkoff BL, Filippatos G, Leclercq C, et al. Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial. Lancet 2023; 402:1147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu F, Zheng L, Ding L, et al. Clinical outcome of left ventricular multipoint pacing versus conventional biventricular pacing in cardiac resynchronization therapy: a systematic review and meta-analysis. Heart Fail Rev 2018; 23:927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auricchio A, Stellbrink C, Sack S, et al. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002; 39:2026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao RK, Kumar UN, Schafer J, et al. Reduced ventricular volumes and improved systolic function with cardiac resynchronization therapy: a randomized trial comparing simultaneous biventricular pacing, sequential biventricular pacing, and left ventricular pacing. Circulation 2007; 115:2136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boriani G, Kranig W, Donal E, et al. A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: the Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial. Am Heart J 2010; 159:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thibault B, Ducharme A, Harel F, et al. Left ventricular versus simultaneous biventricular pacing in patients with heart failure and a QRS complex ≥120 milliseconds. Circulation 2011; 124:2874.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meluzín J, Novák M, Müllerová J, et al. A fast and simple echocardiographic method of determination of the optimal atrioventricular delay in patients after biventricular stimulation. Pacing Clin Electrophysiol 2004; 27:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellenbogen KA, Gold MR, Meyer TE, et al. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation 2010; 122:2660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brenyo A, Kutyifa V, Moss AJ, et al. Atrioventricular delay programming and the benefit of cardiac resynchronization therapy in MADIT-CRT. Heart Rhythm 2013; 10:1136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352:1539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McAlister FA, Ezekowitz J, Hooton N, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA 2007; 297:2502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           León AR, Abraham WT, Curtis AB, et al. Safety of transvenous cardiac resynchronization system implantation in patients with chronic heart failure: combined results of over 2,000 patients from a multicenter study program. J Am Coll Cardiol 2005; 46:2348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perisinakis K, Theocharopoulos N, Damilakis J, et al. Fluoroscopically guided implantation of modern cardiac resynchronization devices: radiation burden to the patient and associated risks. J Am Coll Cardiol 2005; 46:2335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox M, Mealing S, Anderson R, et al. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. Health Technol Assess 2007; 11:iii.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duray GZ, Israel CW, Pajitnev D, Hohnloser SH. Upgrading to biventricular pacing/defibrillation systems in right ventricular paced congestive heart failure patients: prospective assessment of procedural parameters and response rate. Europace 2008; 10:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swindle JP, Rich MW, McCann P, et al. Implantable cardiac device procedures in older patients: use and in-hospital outcomes. Arch Intern Med 2010; 170:631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fish JM, Brugada J, Antzelevitch C. Potential proarrhythmic effects of biventricular pacing. J Am Coll Cardiol 2005; 46:2340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navia JL, Atik FA. Minimally invasive surgical alternatives for left ventricle epicardial lead implantation in heart failure patients. Ann Thorac Surg 2005; 80:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ezelsoy M, Bayram M, Yazici S, et al. Surgical placement of left ventricular lead for cardiac resynchronisation therapy after failure of percutaneous attempt. Cardiovasc J Afr 2017; 28:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McALOON CJ, Anderson BM, Dimitri W, et al. Long-Term Follow-Up of Isolated Epicardial Left Ventricular Lead Implant Using a Minithoracotomy Approach for Cardiac Resynchronization Therapy. Pacing Clin Electrophysiol 2016; 39:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burger H, Pecha S, Hakmi S, et al. Five-year follow-up of transvenous and epicardial left ventricular leads: experience with more than 1000 leads. Interact Cardiovasc Thorac Surg 2020; 30:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rickard J, Johnston DR, Price J, et al. Reverse ventricular remodeling and long-term survival in patients undergoing cardiac resynchronization with surgically versus percutaneously placed left ventricular pacing leads. Heart Rhythm 2015; 12:517.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vijayaraman P, Dandamudi G, Zanon F, et al. Permanent His bundle pacing: Recommendations from a Multicenter His Bundle Pacing Collaborative Working Group for standardization of definitions, implant measurements, and follow-up. Heart Rhythm 2018; 15:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hua W, Zhang S, Huang D. The implantation technique in His-bundle pacing: evolution and perspectives. Europace 2020; 22:ii3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Upadhyay GA, Vijayaraman P, Nayak HM, et al. On-treatment comparison between corrective His bundle pacing and biventricular pacing for cardiac resynchronization: A secondary analysis of the His-SYNC Pilot Trial. Heart Rhythm 2019; 16:1797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beer D, Sharma PS, Subzposh FA, et al. Clinical Outcomes of Selective Versus Nonselective His Bundle Pacing. JACC Clin Electrophysiol 2019; 5:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang S, Zhou X, Gold MR. Left Bundle Branch Pacing: JACC Review Topic of the Week. J Am Coll Cardiol 2019; 74:3039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su L, Wang S, Wu S, et al. Long-Term Safety and Feasibility of Left Bundle Branch Pacing in a Large Single-Center Study. Circ Arrhythm Electrophysiol 2021; 14:e009261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang W, Chen X, Su L, et al. A beginner's guide to permanent left bundle branch pacing. Heart Rhythm 2019; 16:1791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu S, Chen X, Wang S, et al. Evaluation of the Criteria to Distinguish Left Bundle Branch Pacing From Left Ventricular Septal Pacing. JACC Clin Electrophysiol 2021; 7:1166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ponnusamy SS, Basil W, Vijayaraman P. Electrophysiological characteristics of septal perforation during left bundle branch pacing. Heart Rhythm 2022; 19:728.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3500 Version 34.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11788207" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Retiming the failing heart: principles and current clinical status of cardiac resynchronization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14638522" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cardiac resynchronization therapy for heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15829542" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Resynchronizing ventricular contraction in heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37283271" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32748157" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : His bundle pacing for cardiac resynchronization therapy: a systematic literature review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32703568" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Cardiac Resynchronization Therapy in Patients With Nonischemic Cardiomyopathy Using Left Bundle Branch Pacing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21039639" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Greater three-dimensional ventricular lead tip separation is associated with improved outcome after cardiac resynchronization therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18787728" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Valve of Vieussens: an obstacle for left ventricular lead placement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27549013" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Real-World Assessment of Acute Left Ventricular Lead Implant Success and Complication Rates: Results from the Attain Success Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28917564" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Impact of institutional procedural volume on inhospital outcomes after cardiac resynchronization therapy device implantation: US national database 2003-2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26705557" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Prevalence and predictor factors of severe venous obstruction after cardiovascular electronic device implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18554213" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Implant venoplasty: dilation of subclavian and coronary veins to facilitate device implantation: indications, frequency, methods, and complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26231843" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Venous Stenosis After Transvenous Lead Placement: A Study of Outcomes and Risk Factors in 212 Consecutive Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15574174" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Incidence and risk factors of early venous thrombosis associated with permanent pacemaker leads.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14697723" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Incidence of venous obstruction following insertion of an implantable cardioverter defibrillator. A study of systematic contrast venography on patients presenting for their first elective ICD generator replacement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33478714" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Comparative Analysis of Procedural Outcomes and Complications Between De Novo and Upgraded Cardiac Resynchronization Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16008801" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Central venous occlusion is not an obstacle to device upgrade with the assistance of laser extraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20152562" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Lead extraction in the contemporary setting: the LExICon study: an observational retrospective study of consecutive laser lead extractions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20798115" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Supraclavicular vein approach to overcoming ipsilateral chronic subclavian vein obstruction during pacemaker-ICD lead revision or upgrading.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17669077" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The innominate vein as alternative venous access for complicated implantable cardioverter defibrillator revisions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18392929" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Pacemaker and ICD leads: strategies for long-term management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28214565" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Trends and outcomes of cardiac resynchronization therapy upgrade procedures: A comparative analysis using a United States National Database 2003-2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20921437" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30466845" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Left Ventricular Lead Location and Long-Term Outcomes in Cardiac Resynchronization Therapy Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32972554" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Targeted Left Ventricular Lead Implantation Strategy for Non-Left Bundle Branch Block Patients: The ENHANCE CRT Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24446891" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The effect of left ventricular electrical delay on the acute hemodynamic response with cardiac resynchronization therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24668162" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Determination of the longest intrapatient left ventricular electrical delay may predict acute hemodynamic improvement in patients after cardiac resynchronization therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27753447" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : High Left Ventricular Lead Sensing Delay Predicts QRS Narrowing and Good Response to Cardiac Resynchronization Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27906653" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Longer Left Ventricular Electric Delay Reduces Mitral Regurgitation After Cardiac Resynchronization Therapy: Mechanistic Insights From the SMART-AV Study (SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30839112" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Interlead electrical delays and scar tissue: Response to cardiac resynchronization therapy in patients with ischemic cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29377984" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Longer inter-lead electrical delay is associated with response to cardiac resynchronization therapy in patients with presumed optimal left ventricular lead position.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16476852" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16360050" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Magnetic resonance imaging assessment of ventricular dyssynchrony: current and emerging concepts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17631217" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Intraventricular dyssynchrony predicts mortality and morbidity after cardiac resynchronization therapy: a study using cardiovascular magnetic resonance tissue synchronization imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15519016" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16087800" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Real-time three-dimensional echocardiography: a novel technique to quantify global left ventricular mechanical dyssynchrony.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16360052" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Mechanical dyssynchrony assessed by tissue Doppler imaging is a powerful predictor of mortality in congestive heart failure with normal QRS duration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14769701" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Improvement of left ventricular function after cardiac resynchronization therapy is predicted by tissue Doppler imaging echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15582313" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Echocardiographic parameters of ventricular dyssynchrony validation in patients with heart failure using sequential biventricular pacing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15197148" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Tissue Doppler imaging is superior to strain rate imaging and postsystolic shortening on the prediction of reverse remodeling in both ischemic and nonischemic heart failure after cardiac resynchronization therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15374800" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Usefulness of the peak velocity difference by tissue Doppler imaging technique as an effective predictor of response to cardiac resynchronization therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16574689" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Left intraventricular myocardial deformation dyssynchrony identifies responders to cardiac resynchronization therapy in patients with heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16728225" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Tissue synchronization imaging and optimal left ventricular pacing site in cardiac resynchronization therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16476850" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Novel speckle-tracking radial strain from routine black-and-white echocardiographic images to quantify dyssynchrony and predict response to cardiac resynchronization therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18474810" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Comparison of echocardiographic dyssynchrony assessment by tissue velocity and strain imaging in subjects with or without systolic dysfunction and with or without left bundle-branch block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14680737" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Long-term effectiveness of cardiac resynchronization therapy in patients with refractory heart failure and "narrow" QRS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17161254" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Cardiac resynchronization therapy in patients with a narrow QRS complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17161255" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Benefits of cardiac resynchronization therapy for heart failure patients with narrow QRS complexes and coexisting systolic asynchrony by echocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14680738" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Predicting cardiac resynchronization response by QRS duration: the long and short of it.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16360042" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Cardiac resynchronization therapy: Part 1--issues before device implantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17174647" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Scar burden by myocardial perfusion imaging predicts echocardiographic response to cardiac resynchronization therapy in ischemic cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30847659" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Multimodality imaging for real-time image-guided left ventricular lead placement during cardiac resynchronization therapy implantations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20100970" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Analysis of ventricular activation using surface electrocardiography to predict left ventricular reverse volumetric remodeling during cardiac resynchronization therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25974406" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Effectiveness and Reliability of Selected Site Pacing for Avoidance of Phrenic Nerve Stimulation in CRT Patients with Quadripolar LV Leads: The EffaceQ Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20421518" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Agreement is poor among current criteria used to define response to cardiac resynchronization therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23000040" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : QRS narrowing is associated with reverse remodeling in patients with chronic right ventricular pacing upgraded to cardiac resynchronization therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21956038" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Paced left ventricular QRS width and ECG parameters predict outcomes after cardiac resynchronization therapy: PROSPECT-ECG substudy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21382893" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23851059" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Clinical outcomes with synchronized left ventricular pacing: analysis of the adaptive CRT trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26071616" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Impact of a Novel Adaptive Optimization Algorithm on 30-Day Readmissions: Evidence From the Adaptive CRT Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27450156" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Optimization of left ventricular pacing site plus multipoint pacing improves remodeling and clinical response to cardiac resynchronization therapy at 1 year.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37634520" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30209643" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Clinical outcome of left ventricular multipoint pacing versus conventional biventricular pacing in cardiac resynchronization therapy: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12084604" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17420340" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Reduced ventricular volumes and improved systolic function with cardiac resynchronization therapy: a randomized trial comparing simultaneous biventricular pacing, sequential biventricular pacing, and left ventricular pacing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20569719" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A randomized double-blind comparison of biventricular versus left ventricular stimulation for cardiac resynchronization therapy: the Biventricular versus Left Univentricular Pacing with ICD Back-up in Heart Failure Patients (B-LEFT HF) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22104549" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Left ventricular versus simultaneous biventricular pacing in patients with heart failure and a QRS complex≥120 milliseconds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14720156" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : A fast and simple echocardiographic method of determination of the optimal atrioventricular delay in patients after biventricular stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21098426" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23712031" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Atrioventricular delay programming and the benefit of cardiac resynchronization therapy in MADIT-CRT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15152059" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15753115" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The effect of cardiac resynchronization on morbidity and mortality in heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17565085" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16360070" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Safety of transvenous cardiac resynchronization system implantation in patients with chronic heart failure: combined results of over 2,000 patients from a multicenter study program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16360068" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Fluoroscopically guided implantation of modern cardiac resynchronization devices: radiation burden to the patient and associated risks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17999842" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18077483" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Upgrading to biventricular pacing/defibrillation systems in right ventricular paced congestive heart failure patients: prospective assessment of procedural parameters and response rate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20386008" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Implantable cardiac device procedures in older patients: use and in-hospital outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16360069" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Potential proarrhythmic effects of biventricular pacing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16039257" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Minimally invasive surgical alternatives for left ventricle epicardial lead implantation in heart failure patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28262910" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Surgical placement of left ventricular lead for cardiac resynchronisation therapy after failure of percutaneous attempt.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27501471" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Long-Term Follow-Up of Isolated Epicardial Left Ventricular Lead Implant Using a Minithoracotomy Approach for Cardiac Resynchronization Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31633187" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Five-year follow-up of transvenous and epicardial left ventricular leads: experience with more than 1000 leads.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25460866" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Reverse ventricular remodeling and long-term survival in patients undergoing cardiac resynchronization with surgically versus percutaneously placed left ventricular pacing leads.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29107697" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Permanent His bundle pacing: Recommendations from a Multicenter His Bundle Pacing Collaborative Working Group for standardization of definitions, implant measurements, and follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33370796" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : The implantation technique in His-bundle pacing: evolution and perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31096064" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : On-treatment comparison between corrective His bundle pacing and biventricular pacing for cardiac resynchronization: A secondary analysis of the His-SYNC Pilot Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31320004" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Clinical Outcomes of Selective Versus Nonselective His Bundle Pacing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31865972" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Left Bundle Branch Pacing: JACC Review Topic of the Week.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33426907" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Long-Term Safety and Feasibility of Left Bundle Branch Pacing in a Large Single-Center Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31233818" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : A beginner's guide to permanent left bundle branch pacing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33933414" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Evaluation of the Criteria to Distinguish Left Bundle Branch Pacing From Left Ventricular Septal Pacing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35066178" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Electrophysiological characteristics of septal perforation during left bundle branch pacing.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
